--- schema_version: "secwatch.filing_event.v1" accession: "0001493152-22-036016" form_type: "8-K" ticker: "HROW" cik: "0001360214" company_name: "HARROW, INC." filed_at: "2022-12-20T23:59:59+00:00" generated_at: "2026-06-21T01:37:09.110322+00:00" event_type: "debt" sentiment: "neutral" materiality_score: 0.7 calibrated_materiality_score: 0.7 confidence: "high" source: SEC EDGAR --- # Harrow Health issues $35M 11.875% notes and $100M loan facility for acquisition ## Summary - Issued $35M in 11.875% senior notes due 2027 (plus up to $5.25M overallotment); closed Dec 20, 2022. - Entered $100M loan facility at 10.875% through B. Riley Commercial Capital; matures Dec 14, 2025. - Loan proceeds earmarked for acquisition of certain assets from Novartis Technology and Novartis Innovative Therapies. - Loan secured by IP and all assets of Harrow and its material subsidiaries; includes prepayment penalties. - Notes callable at Company's option starting Dec 31, 2024 at specified prices plus accrued interest. ## SEC filing metadata - accession: 0001493152-22-036016 - form_type: 8-K - ticker: HROW - cik: 0001360214 - company_name: HARROW, INC. - filed_at: 2022-12-20T23:59:59+00:00 - event_type: debt - sentiment: neutral - materiality_score: 0.7 - calibrated_materiality_score: 0.7 - confidence: high - sec_items: 1.01, 2.03, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1360214/000149315222036016/0001493152-22-036016-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1360214/000149315222036016/form8-k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001493152-22-036016 - JSON: https://secwatch.observer/filing/0001493152-22-036016.json - Plain text: https://secwatch.observer/filing/0001493152-22-036016.txt ## Key facts - Debt Financings HARROW, INC. incurred senior notes of $35,000,000 aggregate principal amount of 11.875% Senior Notes due 2027 with B. Riley Securities, Inc. at 11.875% per annum maturing December 31, 2027. - Instrument: senior notes - Principal: $35,000,000 aggregate principal amount of 11.875% Senior Notes due 2027 - Counterparty: B. Riley Securities, Inc. - Rate: 11.875% per annum - Maturity: December 31, 2027 - Event: incurrence source text: the Company agreed to sell to the Underwriters $35,000,000 aggregate principal amount of 11.875% Senior Notes due 2027 (the “ Firm Notes ”) plus up to an additional $5,250,000 aggregate principal amount of 11.875% Senior Notes due 2027 evidence_url: https://www.sec.gov/Archives/edgar/data/1360214/000149315222036016/0001493152-22-036016-index.htm - Debt Financings HARROW, INC. incurred credit facility of up to $100,000,000 with B. Riley Commercial Capital, LLC at 10.875% per annum maturing December 14, 2025. - Instrument: credit facility - Principal: up to $100,000,000 - Counterparty: B. Riley Commercial Capital, LLC - Rate: 10.875% per annum - Maturity: December 14, 2025 - Event: incurrence source text: The Loan Agreement provides for a loan facility of up to $100,000,000 to the Company (the “ Loan ”) with a maturity date of December 14, 2025 (the “ Maturity Date ”), at an interest rate of 10.875% per annum. evidence_url: https://www.sec.gov/Archives/edgar/data/1360214/000149315222036016/0001493152-22-036016-index.htm - Material Agreements HARROW, INC. entered into Second Supplemental Indenture with U.S. Bank Trust Company, National Association valued at $35,000,000 aggregate principal amount of 11.875% Senior Notes due 2027 (effective 2022-12-20). - Action: entry - Agreement: notes offering - Counterparty: U.S. Bank Trust Company, National Association - Value: $35,000,000 aggregate principal amount of 11.875% Senior Notes due 2027 - Effective: 2022-12-20 source text: On December 20, 2022, the Company entered into a Second Supplemental Indenture (the “ Second Supplemental Indenture ”) to the indenture dated as of April 20, 2021 (the “ Base Indenture ” and, together with the Second Supplemental Indenture, the “ Indenture ”) with U.S. Bank Trust Company, National Association (as successor to U.S. Bank National Association), as trustee (the “ Trustee ”). evidence_url: https://www.sec.gov/Archives/edgar/data/1360214/000149315222036016/0001493152-22-036016-index.htm - Material Agreements HARROW, INC. entered into Underwriting Agreement with B. Riley Securities, Inc. valued at $35,000,000 aggregate principal amount of 11.875% Senior Notes due 2027 plus up to an additional $5, (effective 2022-12-15). - Action: entry - Agreement: underwriting - Counterparty: B. Riley Securities, Inc. - Value: $35,000,000 aggregate principal amount of 11.875% Senior Notes due 2027 plus up to an additional $5, - Effective: 2022-12-15 source text: on December 15, 2022, Harrow Health, Inc. (the “ Company ”) entered into an underwriting agreement with B. Riley Securities, Inc., as representative of the several underwriters named therein (collectively the “ Underwriters ”), pursuant to which the Company agreed to sell to the Underwriters $35,000,000 aggregate principal amount of 11.875% Senior Notes due 2027 (the “ Firm Notes ”) plus up to an additional $5,250,000 aggregate principal amount of 11.875% Senior Notes due 2027 pursuant to the option to purchase additional Notes evidence_url: https://www.sec.gov/Archives/edgar/data/1360214/000149315222036016/0001493152-22-036016-index.htm - Material Agreements HARROW, INC. entered into Loan and Security Agreement with B. Riley Commercial Capital, LLC valued at a loan facility of up to $100,000,000 to the Company with a maturity date of December 14, 2025, at a (effective 2022-12-14). - Action: entry - Agreement: credit facility - Counterparty: B. Riley Commercial Capital, LLC - Value: a loan facility of up to $100,000,000 to the Company with a maturity date of December 14, 2025, at a - Effective: 2022-12-14 source text: On December 14, 2022 (the “ Effective Date ”), the Company and its material subsidiaries entered into a Loan and Security Agreement (the “ Loan Agreement ”) with B. Riley Commercial Capital, LLC, as Administrative Agent for the Lenders from time to time party thereto. The proceeds of the Loan Agreement are expected to be used to finance the Acquisition (as defined below). The Loan Agreement provides for a loan facility of up to $100,000,000 to the Company (the “ Loan ”) with a maturity date of December 14, 2025 (the “ Maturity Date ”), at an interest rate of 10.875% per annum. evidence_url: https://www.sec.gov/Archives/edgar/data/1360214/000149315222036016/0001493152-22-036016-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.